Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines
Abstract Overexpression of HER2 has been reported in around 25% of human breast cancers. Despite recent advances in HER2 targeted therapy, many patients still experience primary and secondary resistance to such treatments, the mechanisms for which are poorly understood. Here, we investigated the sen...
Guardado en:
Autores principales: | Aryan Stanley, G. Hossein Ashrafi, Alan M. Seddon, Helmout Modjtahedi |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/2f0000ac46d14162b7c8ab0dbd956d8f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
IGF1R and Src inhibition induce synergistic cytotoxicity in HNSCC through inhibition of FAK
por: Christine E. Lehman, et al.
Publicado: (2021) -
Co-expression of HER family members in patients with Dukes' C and D colon cancer and their impacts on patient prognosis and survival.
por: Said Abdullah Khelwatty, et al.
Publicado: (2014) -
A common MET polymorphism harnesses HER2 signaling to drive aggressive squamous cell carcinoma
por: Li Ren Kong, et al.
Publicado: (2020) -
Tescalcin/c-Src/IGF1Rβ-mediated STAT3 activation enhances cancer stemness and radioresistant properties through ALDH1
por: Jei Ha Lee, et al.
Publicado: (2018) -
Disruption of FOXO3a-miRNA feedback inhibition of IGF2/IGF-1R/IRS1 signaling confers Herceptin resistance in HER2-positive breast cancer
por: Liyun Luo, et al.
Publicado: (2021)